XTH15 Antibody

Cytokeratin 15 Antibodies

Cytokeratin 15 (CK15) antibodies are well-characterized tools for epithelial cell research, particularly in dermatology and oncology. Two prominent monoclonal antibodies include:

Key Findings:

• CK15 is a cytoskeletal protein critical for mechanical resilience in epithelial cells.

• Antibody ab52816 detects a 50 kDa band in Western blot and shows no cross-reactivity in CK15-knockout cell lines .

• ab80522 localizes CK15 in hair follicle stem cells and squamous carcinomas .

CD15 Antibodies

CD15 (Lewis X antigen) antibodies target carbohydrate epitopes on granulocytes and certain carcinomas.

Key Findings:

• CD15 is expressed in promyelocytes and adenocarcinomas.

• The CONFIRM anti-CD15 antibody demonstrates 100% specificity for myeloid cells and no cross-reactivity in lymphoid tissues .

Antibodies Targeting Other "XTH"-Like Epitopes

While "XTH15" remains unidentified, bispecific antibodies (e.g., ACE910 for hemophilia A) and engineered antibodies (e.g., anti-FIXa/FX for mimicking FVIII activity) illustrate advanced therapeutic platforms. These involve:

• Framework/complementarity determining region (FR/CDR) shuffling to optimize binding .

• pI engineering for improved pharmacokinetics and manufacturability .

Validation Challenges in Antibody Research

The absence of XTH15 highlights broader issues in antibody characterization:

• Reproducibility: ~20% of commercial antibodies fail specificity tests, necessitating knockout validation .

• Affinity metrics: Recombinant antibodies exhibit 10–100× higher affinity than traditional monoclonals .

Recommendations for Further Investigation

1. Verify the correct nomenclature (e.g., CK15, CD15, or XDH15).

2. Screen proprietary antibody libraries (e.g., YCharOS, NeuroMab) for unpublished candidates .

3. Cross-reference patent databases for experimental designations (e.g., ACE910-like developmental codes) .